Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176546 | 1.00 | PRKCA (0.32) | PRKCA | |
| SCHEMBL26726102 | 0.87 | — | — | |
| SCHEMBL5806133 | 0.85 | PRKCA (0.32) | PRKCA | |
| SCHEMBL3519542 | 0.84 | CYP2C9 (0.38) | PRKCA | |
| SCHEMBL5622083 | 0.80 | — | — | |
| SCHEMBL16031858 | 0.80 | — | — | |
| SCHEMBL9685316 | 0.80 | — | — | |
| SCHEMBL15524499 | 0.79 | — | — | |
| SCHEMBL15524497 | 0.79 | — | — | |
| SCHEMBL4570492 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-01-23 | — | — | US | disclosed |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| EP-3442953-A1 | BIOSYNTHESIS OF CANNABINOID PRODRUGS | Teewinot Technologies Limited (IE) | 2019-02-20 | — | — | EP | disclosed |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2018-07-26 | — | — | US | disclosed |
| EP-2215071-B1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20150175530-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8980942-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120289484-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. | 2012-11-15 | — | — | US | disclosed |
| US-8227627-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ALLTRANZ INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | ALLTRANZ (US) | 2009-06-04 | — | — | US | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | PRKCA 606/4885 |
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1453/4885 |
| US-20120289484-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1453/4885 |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1453/4885 |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1453/4885 |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1453/4885 |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1673/4885 |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | CNR2, CNR1, FAAH | PRKCA 1429/4885 |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1453/4885 |
| US-20150175530-A1 | ANTIBACTERIAL AGENTS | MRPL21, ABCB11, LSS | PRKCA 4556/4885 |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1453/4885 |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1453/4885 |
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | PRKCA 1673/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | PRKCA 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.